Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Meeting the Challenge of Diabetes in Ageing and Diverse Populations: A Review of the Literature from the UK.

Wilkinson E, Waqar M, Sinclair A, Randhawa G.

J Diabetes Res. 2016;2016:8030627. Review.

2.

Psychosocial predictors of nonadherence to medical management among patients on maintenance dialysis.

Alosaimi FD, Asiri M, Alsuwayt S, Alotaibi T, Bin Mugren M, Almufarrih A, Almodameg S.

Int J Nephrol Renovasc Dis. 2016 Oct 31;9:263-272.

3.

Validating a Patient-Reported Comorbidity Measure with Respect to Quality of Life in End-Stage Renal Disease.

Robinski M, Strich F, Mau W, Girndt M.

PLoS One. 2016 Jun 13;11(6):e0157506. doi: 10.1371/journal.pone.0157506.

4.

The Eye is the Window to the Kidney and Brain.

Elias MF, Torres RV, Davey A.

EBioMedicine. 2016 Feb 6;5:24-5. doi: 10.1016/j.ebiom.2016.02.010. No abstract available.

5.

Alterations of Hepatic Metabolism in Chronic Kidney Disease via D-box-binding Protein Aggravate the Renal Dysfunction.

Hamamura K, Matsunaga N, Ikeda E, Kondo H, Ikeyama H, Tokushige K, Itcho K, Furuichi Y, Yoshida Y, Matsuda M, Yasuda K, Doi A, Yokota Y, Amamoto T, Aramaki H, Irino Y, Koyanagi S, Ohdo S.

J Biol Chem. 2016 Mar 4;291(10):4913-27. doi: 10.1074/jbc.M115.696930.

PMID:
26728457
6.

Altitude and regional gradients in chronic kidney disease prevalence in Costa Rica: Data from the Costa Rican Longevity and Healthy Aging Study.

Harhay MN, Harhay MO, Coto-Yglesias F, Rosero Bixby L.

Trop Med Int Health. 2016 Jan;21(1):41-51. doi: 10.1111/tmi.12622.

PMID:
26466575
7.

β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis.

Smith LK, He Y, Park JS, Bieri G, Snethlage CE, Lin K, Gontier G, Wabl R, Plambeck KE, Udeochu J, Wheatley EG, Bouchard J, Eggel A, Narasimha R, Grant JL, Luo J, Wyss-Coray T, Villeda SA.

Nat Med. 2015 Aug;21(8):932-7. doi: 10.1038/nm.3898.

8.

'Reality and desire' in the care of advanced chronic kidney disease.

Marrón B, Craver L, Remón C, Prieto M, Gutiérrez JM, Ortiz A.

NDT Plus. 2010 Oct;3(5):431-5. doi: 10.1093/ndtplus/sfq116.

9.

Altered KLOTHO and NF-κB-TNF-α Signaling Are Correlated with Nephrectomy-Induced Cognitive Impairment in Rats.

Degaspari S, Tzanno-Martins CB, Fujihara CK, Zatz R, Branco-Martins JP, Viel TA, Buck Hde S, Orellana AM, Böhmer AE, Lima Lde S, Andreotti DZ, Munhoz CD, Scavone C, Kawamoto EM.

PLoS One. 2015 May 11;10(5):e0125271. doi: 10.1371/journal.pone.0125271.

10.

Increased cerebral water content in hemodialysis patients.

Reetz K, Abbas Z, Costa AS, Gras V, Tiffin-Richards F, Mirzazade S, Holschbach B, Frank RD, Vassiliadou A, Krüger T, Eitner F, Gross T, Schulz JB, Floege J, Shah NJ.

PLoS One. 2015 Mar 31;10(3):e0122188. doi: 10.1371/journal.pone.0122188.

11.

Risk of dementia in peritoneal dialysis patients compared with hemodialysis patients.

Wolfgram DF, Szabo A, Murray AM, Whittle J.

Perit Dial Int. 2015 Mar-Apr;35(2):189-98. doi: 10.3747/pdi.2014.00213.

12.

Haemodynamics during dialysis and cognitive performance.

Wolfgram DF, Sunio L, Vogt E, Smith HM, Visotcky A, Laud P, Whittle J.

Nephrology (Carlton). 2014 Dec;19(12):771-6. doi: 10.1111/nep.12324.

13.

Neurological disorders in a murine model of chronic renal failure.

Chillon JM, Brazier F, Bouquet P, Massy ZA.

Toxins (Basel). 2014 Jan 3;6(1):180-93. doi: 10.3390/toxins6010180.

14.

The Alzheimer pandemic: is paracetamol to blame?

Jones GR.

Inflamm Allergy Drug Targets. 2014 Feb;13(1):2-14.

15.

Cognitive performance before and during hemodialysis: a randomized cross-over trial.

Drew DA, Tighiouart H, Scott TM, Lou KV, Shaffi K, Weiner DE, Sarnak MJ.

Nephron Clin Pract. 2013;124(3-4):151-8. doi: 10.1159/000356393.

16.

Survival after dialysis discontinuation and hospice enrollment for ESRD.

O'Connor NR, Dougherty M, Harris PS, Casarett DJ.

Clin J Am Soc Nephrol. 2013 Dec;8(12):2117-22. doi: 10.2215/CJN.04110413.

17.

Relationship between cognitive impairment and depression in dialysis patients.

Jung S, Lee YK, Choi SR, Hwang SH, Noh JW.

Yonsei Med J. 2013 Nov;54(6):1447-53. doi: 10.3349/ymj.2013.54.6.1447.

18.

Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence.

Covic A, Rastogi A.

BMC Nephrol. 2013 Jul 18;14:153. doi: 10.1186/1471-2369-14-153. Review.

19.

Prevalence and pattern of neurocognitive impairment in nigerians with stages 3 to 5 chronic kidney disease.

Williams UE, Owolabi MO, Ogunniyi A, Ezunu EO.

ISRN Neurol. 2013 Jun 20;2013:374890. doi: 10.1155/2013/374890.

20.

The influence of subclinical cardiovascular disease and related risk factors on cognition in type 2 diabetes mellitus: The DHS-Mind study.

Hugenschmidt CE, Hsu FC, Hayasaka S, Carr JJ, Freedman BI, Nyenhuis DL, Williamson JD, Bowden DW.

J Diabetes Complications. 2013 Sep-Oct;27(5):422-8. doi: 10.1016/j.jdiacomp.2013.04.004.

Items per page

Supplemental Content

Support Center